Inclusion Criteria:  Advanced chronic Heart Failure with Reduced Ejection Fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 35% at Screening, including documented history of HFrEF (LVEF ≤ 35%) for at least 4 months prior to Screening New York Heart Association Class II-IV Cardiac index ≤ 2.5 liters per minute per square meter (L/min/m^2) and pulmonary capillary wedge pressure ≥ 15 millimeters of mercury (mm Hg) at Day 1 Body mass index 18.0 to 37.0 kilograms per square meter (kg/m^2), inclusive  Exclusion Criteria:  Hemodynamically unstable at Day 1 or in the opinion of the Investigator likely to progress to being hemodynamically unstable during the course of the study Treated with carvedilol in general (Part A) or at a dose higher than a total of 25 milligrams per day (Part B) any time within 14 days of Day 1 through the end of the in-clinic observation Post-dose Period. Receiving any mechanical (respiratory or circulatory) or renal support therapy at Screening or Day 1 Systolic Blood Pressure ≤ 90 millimeter of mercury (mm Hg) or ≥ 160 mm Hg, or Heart Rate < 50 beats per minute (bpm) or > 110 bpm, at Screening or Day 1 Recently treated with inotropic, vasoactive or intravenous diuretic therapy, or expected to require such therapy with these drugs any time from Day 1 through the end of study conduct.